| Health / Medical Topics |
Bcr-Abl (b3a2)-Derived Peptide Vaccine
A peptide vaccine consisting of the bcr-abl b3a2 fusion oncoprotein, frequently expressed in chronic myelogenous leukemia (CML), with potential antineoplastic activity. Vaccination with the bcr-abl (b3a2)-derived peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl b3a2 fusion protein. Fusion genes in CML typically result from the fusion of either BCR exon b2 or BCR exon b3 to ABL exon a2, a 'b3a2' or a 'b2a2' fusion. (NCI Thesaurus)
YOU MAY ALSO LIKE
A peptide vaccine consisting of the bcr-abl b2a2 fusion oncoprotein, frequently expressed in chronic myelogenous leukemia (CML), with potential antineoplastic activity. Vaccination…
Human BCR wild-type allele is located in the vicinity of 22q11.23 and is approximately 138 kb in length. This allele, which encodes…
Significant progress has been made towards delineation of the intrinsic molecular processes that regulate B lymphocyte immune function. Recent observations have provided…
The 160 kD BCR phosphoprotein exhibits a unique serine/threonine kinase activity, at least two SH2 binding sites, and a C-terminal GTPase activating…
This gene plays a role in signal transduction.
BCR Downstream Signaling 1, encoded by BRDG1 gene, functions as a docking protein acting downstream of Tec tyrosine kinase in B cell…
